Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.

Chu Y, Muller S, Tavares A, Barret O, Alagille D, Seibyl J, Tamagnan G, Marek K, Luk KC, Trojanowski JQ, Lee VMY, Kordower JH.

Brain. 2019 Oct 3. pii: awz296. doi: 10.1093/brain/awz296. [Epub ahead of print]

PMID:
31580415
2.

Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy.

Uemura N, Uemura MT, Lo A, Bassil F, Zhang B, Luk KC, Lee VM, Takahashi R, Trojanowski JQ.

J Neuropathol Exp Neurol. 2019 Oct 1;78(10):877-890. doi: 10.1093/jnen/nlz070.

PMID:
31504665
3.

Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy.

Espa E, Clemensson EKH, Luk KC, Heuer A, Björklund T, Cenci MA.

Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27810. [Epub ahead of print]

PMID:
31449702
4.

Oxidative stress and α-synuclein conspire in vulnerable neurons to promote Parkinson's disease progression.

Luk KC.

J Clin Invest. 2019 Aug 5;130:3530-3531. doi: 10.1172/JCI130351. eCollection 2019 Aug 5.

5.

Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders.

Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW, Weston LJ, Owen N, Weissman TA, Luna E, Raber J, Luk KC, McCullough AK, Woltjer RL, Unni VK.

Sci Rep. 2019 Jul 29;9(1):10919. doi: 10.1038/s41598-019-47227-z.

6.

Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC, Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM, Kanaan NM, Paumier KL, El-Agnaf OMA, Sortwell CE.

Neurobiol Dis. 2019 Oct;130:104525. doi: 10.1016/j.nbd.2019.104525. Epub 2019 Jul 2.

7.

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo.

Patterson JR, Polinski NK, Duffy MF, Kemp CJ, Luk KC, Volpicelli-Daley LA, Kanaan NM, Sortwell CE.

J Vis Exp. 2019 Jun 2;(148). doi: 10.3791/59758.

PMID:
31205308
8.

The center of olfactory bulb-seeded α-synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice.

Mason DM, Wang Y, Bhatia TN, Miner KM, Trbojevic SA, Stolz JF, Luk KC, Leak RK.

Brain Pathol. 2019 Mar 10. doi: 10.1111/bpa.12718. [Epub ahead of print]

PMID:
30854742
9.

Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.

Zhang B, Kehm V, Gathagan R, Leight SN, Trojanowski JQ, Lee VM, Luk KC.

Methods Mol Biol. 2019;1948:45-57. doi: 10.1007/978-1-4939-9124-2_5.

10.

Focal ultrasound strikes a new tune for targeted drug delivery.

Luk KC.

Mov Disord. 2018 Oct;33(10):1513-1514. doi: 10.1002/mds.27494. Epub 2018 Oct 4. No abstract available.

PMID:
30288777
11.

Identification of a putative novel genotype 3/rabbit hepatitis E virus (HEV) recombinant.

Luk KC, Coller KE, Dawson GJ, Cloherty GA.

PLoS One. 2018 Sep 11;13(9):e0203618. doi: 10.1371/journal.pone.0203618. eCollection 2018.

12.

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 29;15(1):169. doi: 10.1186/s12974-018-1202-9.

13.

Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.

Ugras S, Daniels MJ, Fazelinia H, Gould NS, Yocum AK, Luk KC, Luna E, Ding H, McKennan C, Seeholzer S, Martinez D, Evans P, Brown D, Duda JE, Ischiropoulos H.

EBioMedicine. 2018 May;31:307-319. doi: 10.1016/j.ebiom.2018.05.007.

14.

Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.

Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, Zhang B, Pitkin RM, Olufemi MF, Luk KC, Trojanowski JQ, Lee VM.

Nature. 2018 May;557(7706):558-563. doi: 10.1038/s41586-018-0104-4. Epub 2018 May 9.

15.

Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.

Butler EK, Gersch J, McNamara A, Luk KC, Holzmayer V, de Medina M, Schiff E, Kuhns M, Cloherty GA.

Hepatology. 2018 Dec;68(6):2106-2117. doi: 10.1002/hep.30082. Epub 2018 Sep 22.

PMID:
29734472
16.

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 1;15(1):129. doi: 10.1186/s12974-018-1171-z. Erratum in: J Neuroinflammation. 2018 May 29;15(1):169.

17.

Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.

Luna E, Decker SC, Riddle DM, Caputo A, Zhang B, Cole T, Caswell C, Xie SX, Lee VMY, Luk KC.

Acta Neuropathol. 2018 Jun;135(6):855-875. doi: 10.1007/s00401-018-1829-8. Epub 2018 Mar 3.

18.

Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.

Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ, Lee VM.

J Neurochem. 2018 Jun;145(6):489-503. doi: 10.1111/jnc.14330. Epub 2018 Jun 10.

19.

Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.

Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, Froula J, Duffy MF, Lee VMY, Martinez TN, Dave KD.

J Parkinsons Dis. 2018;8(2):303-322. doi: 10.3233/JPD-171248.

20.

Development and performance of prototype serologic and molecular tests for hepatitis delta infection.

Coller KE, Butler EK, Luk KC, Rodgers MA, Cassidy M, Gersch J, McNamara AL, Kuhns MC, Dawson GJ, Kaptue L, Bremer B, Wedemeyer H, Cloherty GA.

Sci Rep. 2018 Feb 1;8(1):2095. doi: 10.1038/s41598-018-20455-5.

21.

Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology.

Manfredsson FP, Luk KC, Benskey MJ, Gezer A, Garcia J, Kuhn NC, Sandoval IM, Patterson JR, O'Mara A, Yonkers R, Kordower JH.

Neurobiol Dis. 2018 Apr;112:106-118. doi: 10.1016/j.nbd.2018.01.008. Epub 2018 Jan 16.

22.

Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.

Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM, Brundin P.

Acta Neuropathol. 2018 Jan;135(1):65-83. doi: 10.1007/s00401-017-1792-9. Epub 2017 Dec 5.

23.

Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Nouraei N, Mason DM, Miner KM, Carcella MA, Bhatia TN, Dumm BK, Soni D, Johnson DA, Luk KC, Leak RK.

Exp Neurol. 2018 Jan;299(Pt A):172-196. doi: 10.1016/j.expneurol.2017.10.017. Epub 2017 Oct 19.

24.

Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC, Lee VMY, Trojanowski JQ, Björklund A.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293. doi: 10.1073/pnas.1710442114. Epub 2017 Sep 12.

25.

Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages.

Haenseler W, Zambon F, Lee H, Vowles J, Rinaldi F, Duggal G, Houlden H, Gwinn K, Wray S, Luk KC, Wade-Martins R, James WS, Cowley SA.

Sci Rep. 2017 Aug 21;7(1):9003. doi: 10.1038/s41598-017-09362-3.

26.

Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.

Tapias V, Hu X, Luk KC, Sanders LH, Lee VM, Greenamyre JT.

Cell Mol Life Sci. 2017 Aug;74(15):2851-2874. doi: 10.1007/s00018-017-2541-x. Epub 2017 May 22.

27.

Interference factors regarding the path of insertion of rotational-path removable partial dentures.

Huang CT, Liu FC, Luk KC.

Biomed J. 2017 Feb;40(1):69-75. doi: 10.1016/j.bj.2016.07.003. Epub 2017 Mar 14.

28.

Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity.

Luk KC, Covell DJ, Kehm VM, Zhang B, Song IY, Byrne MD, Pitkin RM, Decker SC, Trojanowski JQ, Lee VM.

Cell Rep. 2016 Sep 20;16(12):3373-3387. doi: 10.1016/j.celrep.2016.08.053.

29.

Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.

Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P.

J Exp Med. 2016 Aug 22;213(9):1759-78. doi: 10.1084/jem.20160368. Epub 2016 Aug 8.

30.

Erratum to: Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe.

Mason DM, Nouraei N, Pant DB, Miner KM, Hutchison DF, Luk KC, Stolz JF, Leak RK.

Mol Neurodegener. 2016 Jul 27;11(1):57. No abstract available.

31.

Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe.

Mason DM, Nouraei N, Pant DB, Miner KM, Hutchison DF, Luk KC, Stolz JF, Leak RK.

Mol Neurodegener. 2016 Jun 30;11(1):49. doi: 10.1186/s13024-016-0113-4. Erratum in: Mol Neurodegener. 2016 Jul 27;11(1):57.

32.

Utility of Metagenomic Next-Generation Sequencing for Characterization of HIV and Human Pegivirus Diversity.

Luk KC, Berg MG, Naccache SN, Kabre B, Federman S, Mbanya D, Kaptué L, Chiu CY, Brennan CA, Hackett J Jr.

PLoS One. 2015 Nov 23;10(11):e0141723. doi: 10.1371/journal.pone.0141723. eCollection 2015.

33.

Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.

Luna E, Luk KC.

FEBS Lett. 2015 Dec 21;589(24 Pt A):3749-59. doi: 10.1016/j.febslet.2015.10.023. Epub 2015 Oct 23. Review.

34.

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE.

Neurobiol Dis. 2015 Oct;82:185-199. doi: 10.1016/j.nbd.2015.06.003. Epub 2015 Jun 17.

35.

Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism.

Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, Unni VK.

Cell Rep. 2015 Mar 3;10(8):1252-60. doi: 10.1016/j.celrep.2015.01.060. Epub 2015 Feb 26.

36.

Regioselective direct C-3 arylation of imidazo[1,2-a]pyridines with aryl tosylates and mesylates promoted by palladium-phosphine complexes.

Choy PY, Luk KC, Wu Y, So CM, Wang LL, Kwong FY.

J Org Chem. 2015 Feb 6;80(3):1457-63. doi: 10.1021/jo502386w. Epub 2015 Jan 21.

PMID:
25607730
37.
38.

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.

Zhang Z, Ding Q, Liu JJ, Zhang J, Jiang N, Chu XJ, Bartkovitz D, Luk KC, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B.

Bioorg Med Chem. 2014 Aug 1;22(15):4001-9. doi: 10.1016/j.bmc.2014.05.072. Epub 2014 Jun 11.

PMID:
24997575
39.

Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.

Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, Lee VM.

Cell Rep. 2014 Jun 26;7(6):2054-65. doi: 10.1016/j.celrep.2014.05.033. Epub 2014 Jun 12.

40.

A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples.

Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E, Bouquet J, Greninger AL, Luk KC, Enge B, Wadford DA, Messenger SL, Genrich GL, Pellegrino K, Grard G, Leroy E, Schneider BS, Fair JN, Martínez MA, Isa P, Crump JA, DeRisi JL, Sittler T, Hackett J Jr, Miller S, Chiu CY.

Genome Res. 2014 Jul;24(7):1180-92. doi: 10.1101/gr.171934.113. Epub 2014 Jun 4.

41.

Modeling Lewy pathology propagation in Parkinson's disease.

Luk KC, Lee VM.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S85-7. doi: 10.1016/S1353-8020(13)70022-1. Review.

42.

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

Anderson K, Chen Y, Chen Z, Dominique R, Glenn K, He Y, Janson C, Luk KC, Lukacs C, Polonskaia A, Qiao Q, Railkar A, Rossman P, Sun H, Xiang Q, Vilenchik M, Wovkulich P, Zhang X.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. doi: 10.1016/j.bmcl.2013.10.055. Epub 2013 Nov 1.

PMID:
24239188
43.

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.

Liu JJ, Higgins B, Ju G, Kolinsky K, Luk KC, Packman K, Pizzolato G, Ren Y, Thakkar K, Tovar C, Zhang Z, Wovkulich PM.

ACS Med Chem Lett. 2013 Jan 15;4(2):259-63. doi: 10.1021/ml300351e. eCollection 2013 Feb 14.

44.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.

Padilla F, Bhagirath N, Chen S, Chiao E, Goldstein DM, Hermann JC, Hsu J, Kennedy-Smith JJ, Kuglstatter A, Liao C, Liu W, Lowrie LE Jr, Luk KC, Lynch SM, Menke J, Niu L, Owens TD, O-Yang C, Railkar A, Schoenfeld RC, Slade M, Steiner S, Tan YC, Villaseñor AG, Wang C, Wanner J, Xie W, Xu D, Zhang X, Zhou M, Lucas MC.

J Med Chem. 2013 Feb 28;56(4):1677-92. doi: 10.1021/jm301720p. Epub 2013 Feb 12.

PMID:
23350847
45.

The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress.

Luk KC, Rymar VV, van den Munckhof P, Nicolau S, Steriade C, Bifsha P, Drouin J, Sadikot AF.

J Neurochem. 2013 Jun;125(6):932-43. doi: 10.1111/jnc.12160. Epub 2013 Mar 6.

46.

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM.

Science. 2012 Nov 16;338(6109):949-53. doi: 10.1126/science.1227157.

47.

Rational design of highly selective spleen tyrosine kinase inhibitors.

Lucas MC, Goldstein DM, Hermann JC, Kuglstatter A, Liu W, Luk KC, Padilla F, Slade M, Villaseñor AG, Wanner J, Xie W, Zhang X, Liao C.

J Med Chem. 2012 Dec 13;55(23):10414-23. doi: 10.1021/jm301367c. Epub 2012 Nov 27.

PMID:
23151054
48.

In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer.

Lee D, Das Gupta J, Gaughan C, Steffen I, Tang N, Luk KC, Qiu X, Urisman A, Fischer N, Molinaro R, Broz M, Schochetman G, Klein EA, Ganem D, Derisi JL, Simmons G, Hackett J Jr, Silverman RH, Chiu CY.

PLoS One. 2012;7(9):e44954. doi: 10.1371/journal.pone.0044954. Epub 2012 Sep 18.

49.

Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1.

Das Gupta J, Luk KC, Tang N, Gaughan C, Klein EA, Kandel ES, Hackett J Jr, Silverman RH.

PLoS One. 2012;7(5):e36072. doi: 10.1371/journal.pone.0036072. Epub 2012 May 16.

50.

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice.

Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM.

J Exp Med. 2012 May 7;209(5):975-86. doi: 10.1084/jem.20112457. Epub 2012 Apr 16.

Supplemental Content

Support Center